Leiner Looks For Ibuprofen Growth Following “Negative Mix Impact”
This article was originally published in The Tan Sheet
Executive Summary
Increased ibuprofen opportunities from the planned acquisition of Pharmaceutical Formulations, Inc. (PFI) will help build Leiner's pain management category to $200 mil. by the end of the year, CEO Bob Kaminski claimed Aug. 10
You may also be interested in...
Bird Flu Creates “Opportunity” For AirShield In Immune Category, Leiner Says
The avian flu scare has created an "opportunity" for Leiner's immune system supplement AirShield, the firm said during a second-quarter 2006 earnings call
Bird Flu Creates “Opportunity” For AirShield In Immune Category, Leiner Says
The avian flu scare has created an "opportunity" for Leiner's immune system supplement AirShield, the firm said during a second-quarter 2006 earnings call
Bird Flu Creates “Opportunity” For AirShield In Immune Category, Leiner Says
The avian flu scare has created an "opportunity" for Leiner's immune system supplement AirShield, the firm said during a second-quarter 2006 earnings call